GLP-1 vs. GLP-2: What’s the Difference, and Which One Are You On?

By the Affordable GLP-1 Providers desk · label and trial figures human-verified before launch per our editorial policy · not medical advice

The names differ by one digit and the internet blends them constantly. They are different hormones doing different jobs, treated by different drugs for different diseases — here is the clean split.

Same factory, different products

Both hormones are cut from the same precursor (proglucagon) in the gut’s L-cells and released together after meals — which is where the resemblance ends. GLP-1 talks to the pancreas and brain: insulin release, slowed gastric emptying, satiety. GLP-2 talks to the intestine itself: mucosal growth, absorption capacity, gut-barrier maintenance.

The GLP-1 drug family (this is you)

If you take semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound — GLP-1 plus GIP, not GLP-2), liraglutide, dulaglutide, or exenatide, you are on GLP-1 receptor pharmacology — the diabetes-and-weight class this entire site prices. Note the tirzepatide detail: its second target is GIP, a different incretin again; no approved weight drug touches GLP-2.

The GLP-2 drug, singular

GLP-2’s clinical use is teduglutide (Gattex), a daily injection for short bowel syndrome: it grows absorptive capacity in intestine that surgery shortened, reducing dependence on IV nutrition. Different disease, different specialty, different price universe — and zero overlap with weight management.

Why the confusion is commercially convenient

Supplement marketing loves the blur: "GLP support," "incretin boosters," products name-dropping both hormones to borrow semaglutide’s halo. A reliable filter: anything sold without a prescription that claims GLP-anything effects is selling the letters, not the pharmacology [verify any specific product claims independently].

The GIP wrinkle, since it’s the real second act

The incretin worth actually learning next is GIP — tirzepatide’s co-target and the plausible reason its efficacy curve leads the class. Triple-agonist candidates (adding glucagon receptor activity) are in trials; GLP-2 remains happily employed in gastroenterology, uninvolved in any of it.

The one-sentence answers

Weight or diabetes medication → GLP-1 (possibly plus GIP). Short-bowel intestinal-failure medication → GLP-2. Supplement claiming either without a prescription → neither, and probably nothing.

From receptor to real life

The incretin family is bigger than the marketing suggests, and the receptor list is the decoder ring. GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide, exenatide — slow gastric emptying, amplify glucose-dependent insulin release, and quiet appetite signaling in the brain: the weight-and-diabetes lane. GIP is the second incretin; tirzepatide’s distinction is agonizing GIP and GLP-1 receptors at once, which is the mechanistic story behind its trial averages. GLP-2 is the family member marketing keeps misfiling: released from the same intestinal L-cells, but its job is intestinal growth and absorption — which is why the one approved GLP-2 agonist, teduglutide (Gattex), treats short bowel syndrome and does nothing for weight. And the pipeline’s triple agonists (GLP-1/GIP/glucagon, e.g., retatrutide) remain investigational [verify current status] — a name to recognize, not a product to buy.

The receptor map also explains the side-effect map: slowed gastric emptying is one mechanism wearing two hats — the satiety you want and the nausea you manage are the same lever — and it’s why anesthesia teams care, why oral-drug absorption can shift, and why escalation pacing matters. When a supplement or telehealth ad reaches for this vocabulary (“GLP-1 boosting,” “GLP-2 support”), apply the two-question test: which receptor, shown by what human data? Molecules with receptor agonism strong enough to matter are prescription drugs with labels; everything else is borrowing the family name.

The suffixes are a free decoder: -glutide marks GLP-1 receptor agonists (sema-, lira-, dula-), -tide covers the wider peptide family (tirzepa-, teduglu-, retatru-), and none of it appears on supplement labels because supplements can’t be these molecules. The class began, improbably, with exendin-4 from Gila-monster saliva — a peptide that resisted breakdown long enough to be useful — and two decades of engineering that durability is why once-weekly dosing exists at all. Modern agonists carry albumin-binding modifications that stretch half-lives to about a week; the convenience is chemistry, not marketing.

A field guide to telling the family apart

Pin the names to receptors and the confusion collapses. Semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta/Bydureon, largely historical): GLP-1 receptor agonists — diabetes and weight. Tirzepatide (Mounjaro, Zepbound): GLP-1 plus GIP — same lanes, dual mechanism. Teduglutide (Gattex): GLP-2 — short bowel syndrome, prescribed by GI specialists, no weight indication and no reason to want one, since GLP-2’s trophic, absorption-enhancing action points the opposite direction from appetite suppression.

So “which one am I on?” has a practical answer: if your prescription is for weight or type 2 diabetes, you are on a GLP-1 pathway drug (possibly dual with GIP) — full stop. Nobody is casually on a GLP-2 agonist; that therapy follows intestinal failure, not a BMI. When a product implies otherwise — “GLP-2 gut-healing support” sold beside weight-loss peptides, or compounded blends name-dropping the whole family — you are looking at vocabulary rented for credibility. Ask which receptor, at what evidence level, in which humans; drugs that genuinely move these receptors carry labels, boxed warnings, and prescribers, and anything that doesn’t is trading on the family name.

One more disambiguation worth keeping: DPP-4 inhibitors (sitagliptin and friends) work on this system too — by slowing the breakdown of your own incretins — but deliver far smaller effects than receptor agonists, which is why no one loses 15% body weight on a “gliptin.” Mechanism family, different weight class.

Copies, biosimilars, and the word “generic”

One last taxonomy that saves money and grief: an FDA-approved biosimilar (none yet exists for semaglutide or tirzepatide in the US [verify current status]) is a reviewed, licensed product; a compounded copy is a pharmacy preparation that has never been through FDA review — different legal category, different evidence status, different risk. Sellers blur the three words on purpose. When semaglutide’s patents eventually open the biosimilar door, that will be news with an FDA license attached; until then, “generic Ozempic” is a phrase doing unlicensed work, and the only lawful discount path is the 503A compounding lane this site prices — clearly labeled as the not-FDA-approved thing it is.

Safety, before anything else. Semaglutide and tirzepatide carry a boxed warning: thyroid C-cell tumors occurred in rodents, and the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop and seek care for severe, persistent abdominal pain (with or without vomiting) — the classic pancreatitis presentation. Gallbladder disease, dehydration-driven kidney injury, and hypoglycemia when combined with insulin or sulfonylureas are on the labels. Tell every clinician you take a GLP-1 before any procedure requiring sedation — anesthesia societies advise holding these drugs beforehand because of delayed stomach emptying [verify current guidance]. Do not use in pregnancy. In an emergency, call 911. Report side effects to your clinician and FDA MedWatch (1-800-FDA-1088).

Where this fits the pricing picture. Everything above describes the FDA-approved brand products and their labels. The compounded semaglutide and tirzepatide sold by the telehealth programs in our price index are not FDA-approved, are not reviewed for safety or effectiveness, and vary by pharmacy — trial results and label percentages do not transfer to them. If cost is what brought you here, start with the true-month calculator and the dose-and-cost ladders, and read the full safety page before comparing a single price. One more habit that pays: before enrolling anywhere, check whether the program publicly names its dispensing pharmacy — our pharmacy disclosure index tracks who does, because in a market of not-FDA-approved preparations, the pharmacy is the product and silence about it is information.

The bottom line

GLP-1 vs. GLP-2 is a topic where the label, the trials, and the marketing routinely tell three different stories. The version above sticks to the first two, flags what still needs verification, and leaves the clinical decisions where they belong — with a prescriber who knows your history. When you’re ready to compare what any of this costs in practice, the price index carries every price we track with its source and its date.

Questions worth bringing to your prescriber

Mechanism questions are legitimate clinic questions — ask them. Which receptor(s) does my prescription act on, and what should that predict about effects and side effects for me? Is there a reason to prefer single-agonist versus dual-agonist therapy in my case? If I plateau, is switching mechanisms on the table — and how would we sequence it? What outcome are we actually steering by — weight, A1C, blood pressure, function — and how will we measure it? Anything in my history that changes the risk calculus — pancreatic, thyroid, gallbladder, eye? Prescribers answer these well; marketing pages answer them beautifully and wrong. The difference is who’s accountable for the answer.

How to read this article — and everything else on this site

House rules, so you can audit us: label claims cite labels, trial numbers cite the named trial, and a bracketed [verify] marks a figure our desk re-checks against the current source before each publication cycle rather than trusting memory. Dates matter as much as numbers — labels get revised, prices move — so treat anything undated (here or anywhere) as a rumor with good typography. Nothing above transfers to compounded copies: they are pharmacy preparations that are not FDA-approved, and a trial that tested the brand tested the brand. If you catch an error, [email protected] reaches a human with a 72-hour target; the corrections log shows we mean it.

Two more reading habits pay for themselves. First, separate frequency from severity: a 40% side effect that fades in a week and a 1% one that ends up in an emergency department are different kinds of facts, and sentences that blur them are selling something. Second, notice denominators — “in trials” means the approved product at protocol doses in monitored adults, which is the strongest evidence available and still not a promise about a different product, a different dose, or you.

Frequently asked questions

Is tirzepatide a GLP-2 drug?

No — tirzepatide targets GLP-1 and GIP receptors. GIP is a different incretin; GLP-2’s only major drug is teduglutide, for short bowel syndrome.

Do GLP-2 drugs cause weight loss?

No — teduglutide’s job is increasing intestinal absorption in short bowel syndrome; if anything it supports weight and nutrition status, the opposite direction.

Which hormone do "GLP support" supplements affect?

As marketed — effectively neither. Prescription receptor agonists are engineered peptides; over-the-counter products borrowing the letters have no comparable pharmacology [verify any specific claim].

Sources. FDA prescribing information for the products named; primary trial publications (STEP, SURMOUNT, SUSTAIN programs); FDA approval documents for teduglutide. Human-verified before launch per our editorial policy.